title: A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction (PARAGON-HF)

acronym: PARAGON-HF

summary: The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.

ReferenceCitation: Desai AS, Vaduganathan M, Cleland JG, Claggett BL, Barkoudah E, Finn P, McCausland FR, Yilmaz MB, Lefkowitz M, Shi V, Pfeffer MA, McMurray JJV, Solomon SD. Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. Circ Heart Fail. 2021 Nov 22:CIRCHEARTFAILURE121008597. doi: 10.1161/CIRCHEARTFAILURE.121.008597. [Epub ahead of print]

name: Cardiovascular Division, Brigham and Women’s Hospital, Boston, MA. (A.S.D., M.V., B.L.C., E.B., P.F., M.A.P., S.D.S.)

family: Desai

full_name: Akshay S. Desai

given: Akshay S.

family: Vaduganathan

full_name: Muthiah Vaduganathan

given: Muthiah

name: Robertson Centre for Biostatistics, Institute of Health and Wellbeing and British Heart Foundation Centre of Research Excellence, University of Glasgow, United Kingdom (J.G.C.).

name: National Heart and Lung Institute, Imperial College, London, United Kingdom (J.G.C.).

family: Cleland

full_name: John G. Cleland

given: John G.

family: Claggett

full_name: Brian L. Claggett

given: Brian L.

family: Barkoudah

full_name: Ebrahim Barkoudah

given: Ebrahim

family: Finn

full_name: Peter Finn

given: Peter

name: Renal Division, Brigham and Women’s Hospital, Boston, MA. (F.R.M.)

family: McCausland

full_name: Finnian R. McCausland

given: Finnian R.

name: Department of Cardiology, Dokuz Eylul University, Izmir, Turkey (M.B.Y.).

family: Yilmaz

full_name: Mehmet B. Yilmaz

given: Mehmet B.

name: Novartis Pharmaceuticals, East Hanover, NJ (M.L., V.S.).

family: Lefkowitz

full_name: Martin Lefkowitz

given: Martin

family: Shi

full_name: Victor Shi

given: Victor

family: Pfeffer

full_name: Marc A. Pfeffer

given: Marc A.

name: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.).

family: McMurray

full_name: John J.V. McMurray

given: John J.V.

family: Solomon

full_name: Scott D. Solomon

given: Scott D.

journal_name: Circulation: Heart Failure

title: Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial

ReferenceCitation: Mooney L, Hawkins NM, Jhund PS, Redfield MM, Vaduganathan M, Desai AS, Rouleau JL, Minamisawa M, Shah AM, Lefkowitz MP, Zile MR, Van Veldhuisen DJ, Pfeffer MA, Anand IS, Maggioni AP, Senni M, Claggett BL, Solomon SD, McMurray JJV. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. J Am Heart Assoc. 2021 Nov 19:e021494. doi: 10.1161/JAHA.121.021494. [Epub ahead of print]

name: BHF Glasgow Cardiovascular Research CentreUniversity of Glasgow United Kingdom

family: Mooney

full_name: Leanne Mooney

given: Leanne

name: Division of Cardiology University of British Columbia Vancouver Canada

family: Hawkins

full_name: Nathaniel M. Hawkins

given: Nathaniel M.

family: Jhund

full_name: Pardeep S. Jhund

given: Pardeep S.

name: Department of Cardiovascular Medicine Mayo Clinic Rochester MN

family: Redfield

full_name: Margaret M. Redfield

given: Margaret M.

name: Division of Cardiovascular Medicine Brigham and Women’s Hospital Boston MA

name: Institut de CardiologieUniversité de Montréal Québec Canada

family: Rouleau

full_name: Jean L. Rouleau

given: Jean L.

family: Minamisawa

name: Novartis Pharmaceuticals East Hanover NJ

name: Department of Medicine Medical University of South Carolina Charleston SC

name: University Medical Center GroningenUniversity of Groningen the Netherlands

name: Cardiovascular Department & Cardiology Unit Papa Giovanni XXIII Hospital Bergamo Italy

journal_name: Journal of the American Heart Association

repository_institution: The University of Glasgow - Enlighten: Publications

repositories_institution: The University of Glasgow - Enlighten: Publications

title: Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF

ReferenceCitation: Jackson AM, Jhund PS, Anand IS, Düngen HD, Lam CSP, Lefkowitz MP, Linssen G, Lund LH, Maggioni AP, Pfeffer MA, Rouleau JL, Saraiva JFK, Senni M, Vardeny O, Wijkman MO, Yilmaz MB, Saito Y, Zile MR, Solomon SD, McMurray JJV. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021 Sep 21;42(36):3741-3752. doi: 10.1093/eurheartj/ehab499.

name: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK

name: University of Minnesota, Minneapolis, MN, USA

name: Department of Cardiology, Charité – Universitätsmedizin Berlin, Berlin, Germany

name: National Heart Center Singapore and Duke–National University of Singapore, Singapore, Singapore

name: Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

name: Novartis Pharmaceuticals, East Hanover, NJ, USA

name: Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands

name: Department of Medicine, Karolinska Institutet, Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden

name: Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy

name: Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

name: Institut de Cardiologie de Montréal, Université de Montréal, Québec, Canada

name: Disciplina de Cardiologia Faculdade de Medicina, Pontifícia Universidade Católica de Campinas, Sao Paulo, Brazil

name: Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy

name: Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota, Minneapolis, MN, USA

name: Department of Internal Medicine and Department of Health, Medicine and Caring Sciences, Linköping University, Norrköping, Sweden

name: Department of Cardiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

name: Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan

name: Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA

title: Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

ReferenceCitation: Selvaraj S, Claggett BL, Packer M, Zannad F, Anand IS, Pieske B, Zhao Z, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc. 2021 Sep 7;10(17):e022069. doi: 10.1161/JAHA.121.022069. Epub 2021 May 16.

name: Division of Cardiology Department of Medicine Hospital of the University of Pennsylvania Philadelphia PA

name: Division of Cardiology Department of Medicine Brigham and Women’s Hospital Boston MA

name: Baylor Heart and Vascular InstituteBaylor University Medical Center Dallas TX

name: INSERM Centre d'Investigation Clinic 1433 and Universite de LorraineCentre Hospitalier Regional et Universitaire Nancy France

name: Department of Cardiovascular Medicine University of Minnesota Minneapolis MN

name: Department of Internal Medicine and Cardiology German Center for Cardiovascular Research partner site Berlin Berlin Germany

name: BHF Cardiovascular Research Centre University of Glasgow Glasgow UK

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Diderot

title: Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction

ReferenceCitation: Shen L, Jhund PS, Anand IS, Bhatt AS, Desai AS, Maggioni AP, Martinez FA, Pfeffer MA, Rizkala AR, Rouleau JL, Swedberg K, Vaduganathan M, Vardeny O, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Solomon SD, McMurray JJV. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. J Am Coll Cardiol. 2021 Apr 27;77(16):1961-1973. doi: 10.1016/j.jacc.2021.03.001.

journal_name: Journal of the American College of Cardiology

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

repository_institution: University of Groningen / Centre for Information Technology - University of Groningen research database

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

repositories_institution: University of Groningen / Centre for Information Technology - University of Groningen research database

title: Incidence and Outcomes of Pneumonia in Patients With Heart Failure

ReferenceCitation: Tromp J, Claggett BL, Liu J, Jackson AM, Jhund PS, Køber L, Widimský J, Boytsov SA, Chopra VK, Anand IS, Ge J, Chen CH, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Rizkala AR, Inubushi-Molessa A, Lefkowitz MP, Shi VC, McMurray JJV, Solomon SD, Lam CSP; PARAGON-HF Investigators. Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Circ Heart Fail. 2021 Apr;14(4):e007901. doi: 10.1161/CIRCHEARTFAILURE.120.007901. Epub 2021 Apr 19.

name: National Heart Centre Singapore (J.T., C.S.P.L.).

name: Duke-NUS Medical School, Singapore (J.T., C.S.P.L.).

name: Department of Cardiology, University Medical Centre Groningen, University of Groningen, the Netherlands (J.T., D.J.V.V., C.S.P.L.).

name: Saw Swee Hock School of Public Health, National University of Singapore, Singapore (J.T.).

name: Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (B.L.C., J.L., M.A.P., S.D.S.).

name: British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (A.M.J., P.S.J., J.J.V.M.).

name: Department of Cardiology, Heart Centre, Rigshospitalet, Copenhagen University Hospital, Denmark (L.K.).

name: First Faculty of Medicine, Charles University Prague, Czech Republic (J.W.).

name: National Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow (S.B.).

name: Heart Failure and Research Max Super Specialty Hospital Saket, New Delhi, India (V.C.).

name: Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis (I.S.A.).

name: Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China (J.G.).

name: Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China (C.-H.C.).

name: Associazione Nazionale Medici Cardiologi Ospedalieri, Florence, Italy (A.P.M.).

name: Universidad Nacional of Cordoba, Argentina (F.M.).

name: Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).

name: Department of Internal Medicine, Cardiology Charité, Universitaetsmedizin Berlin, Campus Virchow Klinikum Berlin, Germany (B.P.).

name: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (M.M.R.).

name: Institut de Cardiologie de Montréal, Université de Montréal, QC, Canada (J.L.R.).

name: Inserm CIC 1433 and Université de Lorraine, Centre Hospitalier Régional Universitaire, Nancy, France (F.Z.).

name: Medical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Center, Charleston (M.R.Z.).

name: Novartis Pharmaceuticals Corporation, East Hanover, NJ (A.R.R., A.I.-M., M.P.L., V.C.S.).

name: on behalf of the PARAGON-HF Investigators

title: Global Differences in Heart Failure With Preserved Ejection Fraction

ReferenceCitation: Vaduganathan M, Cunningham JW, Claggett BL, Causland FM, Barkoudah E, Finn P, Zannad F, Pfeffer MA, Rizkala AR, Sabarwal S, McMurray JJV, Solomon S, Desai AS. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2021 May;9(5):374-382. doi: 10.1016/j.jchf.2021.01.014. Epub 2021 Apr 7.

title: Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction

ReferenceCitation: Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction. Eur Heart J Suppl. 2020 Nov 18;22(Suppl L):L77-L81. doi: 10.1093/eurheartj/suaa140. eCollection 2020 Nov.

name: Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico di Milano UOC di Nefrologia, Dialisi e Trapianto Renale dell’adulto Dipartimento Di Medicina e Specialità Mediche, Milan, Italy

name: Department of Molecular Medicine, University of Pavia, Pavia, Italy

name: Cardiovascular Department, IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy

name: Cardiothoracic Department, University Cardiology Unit, University Policlinic Hospital of Bari, Bari, Italy

title: The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction

ReferenceCitation: Jering K, Claggett B, Redfield MM, Shah SJ, Anand IS, Martinez F, Sabarwal SV, Seferović PM, Kerr Saraiva JF, Katova T, Lefkowitz MP, Pfeffer MA, McMurray JJV, Solomon SD. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. JACC Heart Fail. 2021 May;9(5):386-397. doi: 10.1016/j.jchf.2021.01.011. Epub 2021 Mar 10.

title: Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy

ReferenceCitation: Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A, Barkoudah E, McMurray JJV, Pfeffer MA, Solomon SD. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC Heart Fail. 2021 Jan;9(1):13-24. doi: 10.1016/j.jchf.2020.08.014. Epub 2020 Nov 11.

title: Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF

ReferenceCitation: Mc Causland FR, Lefkowitz MP, Claggett B, Anavekar NS, Senni M, Gori M, Jhund PS, McGrath MM, Packer M, Shi V, Van Veldhuisen DJ, Zannad F, Comin-Colet J, Pfeffer MA, McMurray JJV, Solomon SD. Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation. 2020 Sep 29;142(13):1236-1245. doi: 10.1161/CIRCULATIONAHA.120.047643. Epub 2020 Aug 17.

name: Renal Division, Department of Medicine(F.R.M., M.M.M.), Brigham and Women’s Hospital, Boston, MA.

name: Harvard Medical School, Boston, MA (F.R.M., B.C., M.M.M., F.Z., M.A.P., S.D.S.).

name: Novartis Pharmaceuticals, East Hanover, NJ (M.P.L., V.S.).

name: Cardiovascular Division, Department of Medicine (B.C., M.A.P., S.D.S.), Brigham and Women’s Hospital, Boston, MA.

name: Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia (N.S.A.).

name: Cardiology Division, Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy (M.S., M.G.).

name: British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK (P.S.J., J.J.V.M.).

name: Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (D.J.W.).

name: Université de Lorraine, Inserm CIC1433, CHRU de Nancy, France (F.Z.).

name: Department of Cardiology, Bellvitge University Hospital and Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain (J.C.-C.).

name: Department of Clinical Sciences, School of Medicine, University of Barcelona, Spain (J.C.-C.).

title: Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction

ReferenceCitation: Cunningham JW, Claggett BL, O'Meara E, Prescott MF, Pfeffer MA, Shah SJ, Redfield MM, Zannad F, Chiang LM, Rizkala AR, Shi VC, Lefkowitz MP, Rouleau J, McMurray JJV, Solomon SD, Zile MR. Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF. J Am Coll Cardiol. 2020 Aug 4;76(5):503-514. doi: 10.1016/j.jacc.2020.05.072.

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

title: Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF

ReferenceCitation: Cunningham JW, Vaduganathan M, Claggett BL, Zile MR, Anand IS, Packer M, Zannad F, Lam CSP, Janssens S, Jhund PS, Kober L, Rouleau J, Shah SJ, Chopra VK, Shi VC, Lefkowitz MP, Prescott MF, Pfeffer MA, McMurray JJV, Solomon SD. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020 May;8(5):372-381. doi: 10.1016/j.jchf.2020.03.002. Epub 2020 Mar 30.

ReferenceCitation: Selvaraj S, Claggett BL, Böhm M, Anker SD, Vaduganathan M, Zannad F, Pieske B, Lam CSP, Anand IS, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. J Am Coll Cardiol. 2020 Apr 14;75(14):1644-1656. doi: 10.1016/j.jacc.2020.02.009. Epub 2020 Mar 16.

title: Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan

ReferenceCitation: Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. J Am Coll Cardiol. 2019 Dec 10;74(23):2858-2873. doi: 10.1016/j.jacc.2019.09.063.

title: Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction

ReferenceCitation: Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A Pfeffer M, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020 Feb 4;141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586. Epub 2019 Nov 17.

name: Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (S.D.S., M.V., B.L.C., M.A.P., A.D.).

name: Imperial College, London, United Kingdom (M.P.).

name: Medical University of South Carolina, Charleston (M.Z.).

name: Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC (M.Z.).

name: Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.).

name: National Heart and Lung Institute, Imperial College, London, United Kingdom (K.S.).

name: Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.R.).

name: Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden (L.H.L.).

name: Department of Medicine, VA Medical Center and University of Minnesota, Minneapolis (I.A.).

name: Sarver Heart Center, University of Arizona College of Medicine, Tucson (N.S.).

name: Department of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands (G.L.).

name: Heart and Vascular Center, Semmelweis University, Budapest, Hungary (B.M.).

name: University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital of Bucharest, Romania (D.V.).

name: Department of Medicine, National Yang-Ming University, Taipei, Taiwan, Republic of China (C.-H.C.).

name: Cardiology Division, Cardiovascular Department, Hospital Papa Giovanni XXIII, Bergamo, Italy (M.S.).

name: St Luke’s Heart Institute, St. Luke’s Medical Center, Taguig, Philippines (A.S.).

name: Novartis Pharmaceuticals Corporation, East Hanover, NJ (V.S, A.R., M.L.).

title: Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

ReferenceCitation: McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020 Feb 4;141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491. Epub 2019 Nov 17.

name: BHF Cardiovascular Research Centre, University of Glasgow, UK (J.J.V.M., A.M.J., P.S.J.).

name: National Heart Center Singapore and Duke–National University of Singapore (C.S.P.L.).

name: Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands (C.S.P.L., D.J.v.V.).

name: The George Institute for Global Health, Newtown, Australia (C.S.P.L.).

name: University of Minnesota, Minneapolis (I.S.A.).

name: Shanghai Institute of Cardiovascular Diseases, China (J.G.).

name: Novartis Pharmaceuticals, East Hanover, NJ (M.P.L., A.R.R., S.V.S., V.C.S.).

name: National Association of Hospital Cardiologists Research Center, Florence, Italy (A.P.M.).

name: National University of Cordoba, Argentina (F.M.).

name: Baylor University Medical Center, Dallas, TX (M.P.).

name: Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (M.A.P., A.M.S., B.C., S.D.S.).

name: Department of Internal Medicine and Cardiology, German Center for Cardiovascular Research Partner Site Berlin, Germany (B.P.).

name: Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.).

name: INSERM Centre d’Investigation Clinic 1433 and Universite de Lorraine, Centre Hospitalier Regional et Universitaire, Nancy, France (F.Z.).

name: Medical University of South Carolina and the Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston (M.R.Z.).

name: Department of Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Croatia (M.C.).

name: Department of Heart Failure–Transplantation, National Cardiovascular Institute, Bratislava, Slovakia (E.G.).

name: Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria (T.K.).

name: Heart and Vascular Center, Semmelweis University, Budapest, Hungary (A.K.).

name: Department of Noninvasive Cardiology, Medical University of Lodz, Poland (M.L.).

name: University of Arizona Sarver Heart, Tucson (N.S.).

name: Minneapolis VA Center for Care Delivery and Outcomes Research, University of Minnesota (O.V.).

ReferenceCitation: Vaduganathan M, Claggett BL, Desai AS, Anker SD, Perrone SV, Janssens S, Milicic D, Arango JL, Packer M, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. J Am Coll Cardiol. 2020 Jan 28;75(3):245-254. doi: 10.1016/j.jacc.2019.11.003. Epub 2019 Nov 11.

ReferenceCitation: Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP; PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.

name: From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...

repository_institution: Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona

repository_institution: University of Zurich - Zurich Open Repository and Archive

repositories_institution: Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona

repositories_institution: University of Zurich - Zurich Open Repository and Archive

title: Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

ReferenceCitation: Chandra A, Vaduganathan M, Lewis EF, Claggett BL, Rizkala AR, Wang W, Lefkowitz MP, Shi VC, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV, Solomon SD; PARAGON-HF Investigators. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.

title: Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction

ReferenceCitation: Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS Jr, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J Jr, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circ Heart Fail. 2018 Jul;11(7):e004962. doi: 10.1161/CIRCHEARTFAILURE.118.004962.

name: Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (S.D.S., M.A.P.).

name: Novartis Pharmaceuticals Corporation, East Hanover, NJ (V.C.S., A.R.R., J.J.G., M.P.L.).

name: Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Australia (N.A.).

name: Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Berlin, Charité Universitätsmedizin Berlin, Germany (S.D.A.).

name: Department of Cardiology and Pneumology, University of Göttingen Medical Center, Germany (S.D.A.).

name: Guatemalan Heart Institute (J.L. Arango).

name: Centro de Atención e Investigación Cardiovascular del Potosi SC and Hospital Ángeles San Luis, México (J.L. Arenas).

name: Department of Cardiology B, Oslo University Hospital, University of Oslo, Norway (D.A.).

name: Heart Failure Unit, Cardiology Department, Rabin Medical Center, Petah Tikva, Israel (T.B.-G.).

name: National Research Center for Cardiology of the Ministry of Health of the Russian Federation, Moscow, Russia (S.A.B.).

name: Heart Failure Unit, Medanta Medicity, Gurugram, Haryana, India (V.K.C.).

name: Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing (J.C.)

name: University of Glasgow, United Kingdom. National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, United Kingdom (J.C.).

name: Community Heart Failure Program, Department of Cardiology, Bellvitge University Hospital and Institut d’Investigació Biomèdica de Bellvitge, University of Barcelona, Spain (J.C.-C.).

name: Attikon University Hospital, National and Kapodistrian University of Athens, Greece (G.F.).

name: School of Medicine, University of Cyprus, Greece (G.F.).

name: Department of Cardiology, University Heart Center Zurich, University Hospital Zurich, Switzerland (A.J.F.).

name: Department of Cardiology, Rangueil University Hospital, Toulouse, France (M.G.).

name: Universidad Nacional Mayor de San Marcos, Lima, Perú (A.G.).

name: Instituto Nacional Cardiovascular INCOR, Lima, Perú (A.G.).

name: Scientia Clinical and Epidemiological Research Institute, Trujillo, Perú (A.G.).

name: Department of Heart Failure/Transplantation, National Cardiovascular Institute, Bratislava, Slovakia (E.G.).

name: Department of Cardiology, University Hospitals Leuven, Belgium (S.J.)

name: Department of Cardiology, Heart Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (L.K.).

name: Institut de Cardiologie de Montréal, Université de Montréal, Québec, Canada (E.O.M., J.L.R.).

name: Department of Cardiovascular Diseases, University Hospital Center Zagreb, Croatia (D.M.).

name: Seoul National University Hospital, Seoul National University College of Medicine, Korea (B.-H.O.).

name: Instituto FLENI, Buenos Aires, Argentina (S.V.P.).

name: Department of Cardiology, City Hospital, Durban, South Africa (N.R.).

name: First Department of Internal Medicine, Nara Medical University, Kashihara, Japan (Y.S.).

name: Disciplina de Cardiologia Faculdade de Medicina, Pontifícia Universidade Católica de Campinas, Sao Paulo, Brazil (J.F.K.S.).

name: Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.S.).

name: Department of Cardiology, University of Belgrade School of Medicine, Belgrade University Medical Center, Serbia (P.M.S.).

name: St Luke’s Heart Institute, St. Luke’s Medical Center, Taguig, Philippines (A.S.S.).

name: Department of Cardiology, National Heart Centre Singapore (D.S.).

name: Sarver Heart Center, University of Arizona College of Medicine, Tucson (N.K.S.).

name: Department of Cardiology, Tampere University Hospital, Finland (J.T.).

name: University Medical Centre, Ljubljana, Slovenia (B.V.).

name: Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey (M.B.Y.).

name: Department of Cardiology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China (J.Z.).

name: Department of Cardiology, Medical University Graz, Austria (R.Z.).

name: National Heart Centre Singapore and Duke-National University of Singapore (C.S.P.L.).

name: Department of Internal Medicine, Cardiology Charité, Universitaetsmedizin Berlin, Campus Virchow Klinikum Berlin, Germany (B.P., H.-D.D.).

name: University Medical Center Groningen, University of Groningen, The Netherlands (D.J.V.V.).

name: Inserm CIC 1433 and Université de Lorraine, Centre Hospitalier Ré gional Universitaire, Nancy, France (F.Z.).

name: British Heart Foundation Cardiovascular Research Centre (J.J.V.M.)

title: Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial

ReferenceCitation: Mütze T, Glimm E, Schmidli H, Friede T. Group sequential designs with robust semiparametric recurrent event models. Stat Methods Med Res. 2019 Aug;28(8):2385-2403. doi: 10.1177/0962280218780538. Epub 2018 Jun 11.

name: Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany

name: Statistical Methodology, Novartis Pharma AG, Basel, Switzerland

name: Institute for Biometrics and Medical Informatics, Medical Faculty, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

name: DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Göttingen, Germany

title: Group sequential designs with robust semiparametric recurrent event models

ReferenceCitation: Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail. 2017 Jul;5(7):471-482. doi: 10.1016/j.jchf.2017.04.013. Epub 2017 Jun 26. Review.

title: Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction

ReferenceCitation: Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail. 2014 Nov;7(6):1042-9. doi: 10.1161/CIRCHEARTFAILURE.114.001276. Review.

name: From the Section of Cardiology, Department of Medicine, University of Verona, Verona, Italy (A.R.); Center for Cardiovascular Innovation, Northwestern Feinberg School of Medicine, Chicago, IL (M.G.); Department of Medicine, Cardiology Division, University of Larissa, Larissa, Greece (F.T.); Department of Medicine, Cardiology Division, Brigham and Womens Hospital, Harvard Medicine School, Boston, MA (S.D.S.); Department of Cardiology, Medical University Graz, Graz, Austria (B.P.); and Department of...

title: Left Atrium in Heart Failure With Preserved Ejection Fraction

ipd_sharing_description:
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

location_country:
Peru
Guatemala
Finland
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
Taiwan
India
Croatia
France
Japan
Poland
Slovakia
Norway
Argentina
Canada
Slovenia
Korea, Republic of
Colombia
South Africa
Sweden
Switzerland
Netherlands
Philippines
Bulgaria
Singapore
Hungary
China
Germany
United States
United Kingdom
Italy
Austria
Brazil
Serbia
Mexico
Czechia
Israel
Spain
Turkey


title: An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Prospective Study Evaluating Retention Rate, Seizure Control and Tolerability of Eslicarbazepine Acetate (ESL) as Adjunctive Treatment to One Baseline Antiepileptic Drug in Adult Patients With Partial-Onset Seizures With or Without Secondary Generalisation

summary: This was a Non-interventional Prospective Study. Centres enrolled adult patients with partial-onset seizures with or without secondary generalisation for whom the clinician had decided to initiate Eslicarbazepine Acetate (ESL) as an adjunctive therapy prior to the decision to take part in this study. Patients enrolled into the study were not sufficiently controlled with one drug licensed for the use as monotherapy in partial-onset seizures. Patients were seen at baseline and then during normal clinical visits at intervals. Patients in this study were assessed for efficacy and tolerability at baseline and then at least 3 and 6 months after the baseline.

status: Completed

study_completion_date_type: Actual

study_type: Observational

time_perspective: Prospective

enrollment_type: Actual

lead_sponsor: Eisai Inc.

location_country:
Sweden
United Kingdom
France
Norway
Ireland
Denmark
Germany
Czech Republic

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Completed


type: Other Identifier

title: A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)

summary: The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.

study_type: Interventional

design_allocation: Randomized

ReferenceType: derived

ReferenceCitation: Peters SA, Bots ML, Lind L, Groenewegen KA, de Korte C, den Ruijter HM; METEOR study group. The impact of variability in ultrasound settings on the measured echolucency of the carotid intima-media. J Hypertens. 2013 Sep;31(9):1861-7. doi: 10.1097/HJH.0b013e3283623548.

family: Peters

full_name: Sanne A.E. Peters

given: Sanne A.E.

sequence: first

family: Bots

full_name: Michiel L. Bots

given: Michiel L.

sequence: additional

family: Lind

full_name: Lars Lind

given: Lars

family: Groenewegen

full_name: Karlijn A. Groenewegen

given: Karlijn A.

family: de Korte

full_name: Chris de Korte

given: Chris

family: den Ruijter

full_name: Hester M. den Ruijter

given: Hester M.

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Journal of Hypertension

publisher: Ovid Technologies (Wolters Kluwer Health)

publisher_dissemination: Wolters Kluwer Health

publisher_group: Wolters Kluwer Health

publisher_normalized: Wolters Kluwer Health

title: The impact of variability in ultrasound settings on the measured echolucency of the carotid intima–media

ReferenceCitation: Lind L, Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, Evans GW, Raichlen JS, Bots ML; METEOR Study Group. Effect of rosuvastatin on the echolucency of the common carotid intima-media in low-risk individuals: the METEOR trial. J Am Soc Echocardiogr. 2012 Oct;25(10):1120-1127.e1. doi: 10.1016/j.echo.2012.07.004. Epub 2012 Aug 9.

family: Palmer

full_name: Mike K. Palmer

given: Mike K.

family: Grobbee

full_name: Diederick E. Grobbee

given: Diederick E.

family: Crouse

full_name: John R. Crouse

given: John R.

suffix: III

family: O'Leary

full_name: Daniel H. O'Leary

given: Daniel H.

family: Evans

full_name: Gregory W. Evans

given: Gregory W.

family: Raichlen

full_name: Joel S. Raichlen

given: Joel S.

journal_name: Journal of the American Society of Echocardiography

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

title: Effect of Rosuvastatin on the Echolucency of the Common Carotid Intima-Media in Low-Risk Individuals: The METEOR Trial

ReferenceCitation: Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, Evans GW, Raichlen JS, Bots ML; METEOR Study Group. Biologically implausible carotid intima-media thickness measurement values: effects on rate of change over time. Curr Med Res Opin. 2012 Jun;28(6):891-9. doi: 10.1185/03007995.2012.689255. Epub 2012 Jun 6.

name:
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht
UtrechtThe Netherlands

name:
Keele University
KeeleUK

name:
Department of Medicine, Wake Forest University School of Medicine
Winston-Salem, NCUSA

name:
Departments of Biostatistical Sciences and Neurology, Wake Forest University School of Medicine
Winston-Salem, NCUSA

title: Biologically implausible carotid intima–media thickness measurement values: effects on rate of change over time

ReferenceCitation: Stein EA, Vidt DG, Shepherd J, Cain VA, Anzalone D, Cressman MD. Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program. Atherosclerosis. 2012 Apr;221(2):471-7. doi: 10.1016/j.atherosclerosis.2011.12.011. Epub 2012 Jan 3.

title: Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: A retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program

ReferenceCitation: Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, Evans GW, Raichlen JS, Lind L, Bots ML; METEOR Study Group. Manual or semi-automated edge detection of the maximal far wall common carotid intima-media thickness: a direct comparison. J Intern Med. 2012 Mar;271(3):247-56. doi: 10.1111/j.1365-2796.2011.02422.x. Epub 2011 Aug 11.

ReferenceCitation: Peters SA, Dogan S, Meijer R, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, Evans GW, Raichlen JS, Bots ML. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. J Atheroscler Thromb. 2011;18(9):784-95. Epub 2011 May 27.

ReferenceCitation: Peters SA, Palmer MK, Grobbee DE, Crouse JR 3rd, Evans GW, Raichlen JS, Bots ML; METEOR Study Group. Effect of number of ultrasound examinations on the assessment of carotid intima-media thickness changes over time: the example of the METEOR study. J Hypertens. 2011 Jun;29(6):1145-54. doi: 10.1097/HJH.0b013e328345d85e.

title: Effect of number of ultrasound examinations on the assessment of carotid intima–media thickness changes over time: the example of the METEOR study

ReferenceCitation: Peters SA, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, Raichlen JS, Bots ML. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med. 2010 Aug;268(2):155-61. doi: 10.1111/j.1365-2796.2010.02230.x. Epub 2010 Mar 6.

ReferenceCitation: Bots ML, Palmer MK, Dogan S, Plantinga Y, Raichlen JS, Evans GW, O'Leary DH, Grobbee DE, Crouse JR 3rd; METEOR Study Group. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med. 2009 Jun;265(6):698-707. doi: 10.1111/j.1365-2796.2009.02073.x. Epub 2009 Mar 2.

ReferenceCitation: Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 Mar 28;297(12):1344-53. Epub 2007 Mar 25.

ReferenceCitation: Crouse JR 3rd, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, Riley WA, Raichlen JS; METEOR Study Group. Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study. Curr Med Res Opin. 2007 Mar;23(3):641-8.

location_country:
Netherlands
Germany
Finland
France
Norway
Belgium
United States
Czech Republic


title: Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure

summary: The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke (time to first event)

primary_purpose: Prevention

ReferenceCitation: Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, Cleland JG, McMurray JJ, Aukrust P, Ueland T. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS One. 2015 Aug 19;10(8):e0133970. doi: 10.1371/journal.pone.0133970. eCollection 2015.

family: Askevold

full_name: Erik Tandberg Askevold

given: Erik Tandberg

family: Gullestad

full_name: Lars Gullestad

family: Nymo

full_name: Ståle Nymo

given: Ståle

family: Kjekshus

full_name: John Kjekshus

given: John

family: Yndestad

full_name: Arne Yndestad

given: Arne

family: Latini

full_name: Roberto Latini

given: Roberto

family: Cleland

full_name: John G. F. Cleland

given: John G. F.

family: McMurray

full_name: John J. V. McMurray

given: John J. V.

family: Aukrust

full_name: Pål Aukrust

given: Pål

family: Ueland

full_name: Thor Ueland

given: Thor

currency_apc_doaj: USD

journal_name: PLOS ONE

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

host_type: publisher

license: cc-by

license_normalized: cc-by

version: publishedVersion

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: Australian Catholic University - Research Bank

repository_institution: University of Oslo - Duo Research Archive

evidence: oa repository (via pmcid lookup)

license_normalized: no license

version: acceptedVersion

evidence: oa repository (semantic scholar lookup)

version: submittedVersion

publisher: Public Library of Science (PLoS)

publisher_dissemination: Public Library of Science

ReferenceCitation: Perez AC, Jhund PS, Stott DJ, Gullestad L, Cleland JG, van Veldhuisen DJ, Wikstrand J, Kjekshus J, McMurray JJ. Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure). JACC Heart Fail. 2014 Feb;2(1):35-40. doi: 10.1016/j.jchf.2013.07.008. Epub 2014 Jan 25.

title: Thyroid-Stimulating Hormone and Clinical Outcomes

ReferenceCitation: Gravning J, Askevold ET, Nymo SH, Ueland T, Wikstrand J, McMurray JJ, Aukrust P, Gullestad L, Kjekshus J; CORONA Study Group. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circ Heart Fail. 2014 Jan;7(1):96-103. doi: 10.1161/CIRCHEARTFAILURE.113.000450. Epub 2013 Nov 27.

name: From the Department of Cardiology (J.G., E.T.A., L.G., J.K.), Research Institute of Internal Medicine (E.T.A., S.H.N., T.U., P.A.), Section of Endocrinology (T.U.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway; Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden (J.W.); British Heart Foundation Glasgow Cardiovascular Research Centre,...

title: Prognostic Effect of High-Sensitive Troponin T Assessment in Elderly Patients With Chronic Heart Failure

ReferenceCitation: Perez AC, Jhund P, Preiss D, Kjekshus J, McMurray JJ. Effect of rosuvastatin on fatigue in patients with heart failure. J Am Coll Cardiol. 2013 Mar 12;61(10):1121-2. doi: 10.1016/j.jacc.2012.12.004.

title: Effect of Rosuvastatin on Fatigue in Patients With Heart Failure

ReferenceCitation: van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013 Mar;6(2):219-26. doi: 10.1161/CIRCHEARTFAILURE.112.000129. Epub 2013 Feb 8.

name: From the Department of Cardiology, Medical Center Groningen, University of Groningen, Groningen, The Netherlands (A.R.v.d.V., D.J.v.V., R.A.d.B.); Oslo University Hospital, Rikshospitalet and K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway (L.G., T.U., P.A.); and BG Medicine, Waltham, MA (Y.G., A.A., P.M.).

title: Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure

ReferenceCitation: Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, Yndestad A, Cleland JG, McMurray JJ, Aukrust P, Gullestad L. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail. 2013 Jan;6(1):91-8. doi: 10.1161/CIRCHEARTFAILURE.112.972653. Epub 2012 Dec 10.

name: From the Department of Cardiology (E.T.A., J.K., L.G.), Research Institute of Internal Medicine (E.T.A., S.N., T.U., A.Y., P.A.), Section of Clinical Immunology and Infectious Diseases (P.A.), Institute for Surgical Research (J.G.), Department of Medical Biochemistry, Oslo University Hospital Rikshospitalet (R.W.), Faculty of Medicine (T.U., J.K., A.Y., P.A., L.G.), and K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research (E.T.A., S.N., J.G., J.K., A.Y., L.G.), University of...

title: Soluble Glycoprotein 130 Predicts Fatal Outcomes in Chronic Heart Failure

ReferenceCitation: Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, McMurray JJ, Wikstrand J, Aukrust P. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J. 2012 Dec;164(6):878-83. doi: 10.1016/j.ahj.2012.08.021. Epub 2012 Oct 29.

ReferenceCitation: Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, Vårdal M, Bottazzi B, Mantovani A, Lucci D, Masuda N, Sudo Y, Wikstrand J, Tognoni G, Aukrust P, Tavazzi L; Investigators of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) trials. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. Eur J Heart Fail. 2012 Sep;14(9):992-9. Epub 2012 Jun 27.

ReferenceCitation: Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail. 2011 Mar;4(2):145-52. doi: 10.1161/CIRCHEARTFAILURE.110.957332. Epub 2011 Jan 7.

name: From the Research Institute for Internal Medicine (T.U., C.D., P.A.), Section of Endocrinology (T.U.), Department of Cardiology (J.K., L.G.), and Section of Clinical Immunology and Infectious Diseases (P.A.), Rikshospitalet University Hospital, University of Oslo, Oslo, Norway; Wallenberg Laboratory for Cardiovascular Research (J.H., J.W.), Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden; AstraZeneca (M.L.), Mölndal, Sweden; Klinik für Innere Medizin III (M.B.), Universitätsklinikum...

title: Osteoprotegerin Predicts Progression of Chronic Heart Failure: Results From CORONA

ReferenceCitation: McMurray JJ, Dunselman P, Wedel H, Cleland JG, Lindberg M, Hjalmarson A, Kjekshus J, Waagstein F, Apetrei E, Barrios V, Böhm M, Kamenský G, Komajda M, Mareev V, Wikstrand J; CORONA Study Group. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). J Am Coll Cardiol. 2010 Oct 5;56(15):1196-204. doi: 10.1016/j.jacc.2010.02.075.

title: Coenzyme Q10, Rosuvastatin, and Clinical Outcomes in Heart Failure

ReferenceCitation: Inglis SC, McMurray JJ, Böhm M, Schaufelberger M, van Veldhuisen DJ, Lindberg M, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wedel H, Wikstrand J; CORONA Study Group. Intermittent claudication as a predictor of outcome in patients with ischaemic systolic heart failure: analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA). Eur J Heart Fail. 2010 Jul;12(7):698-705. doi: 10.1093/eurjhf/hfq070. Epub 2010 May 25.

name: BHF Glasgow Cardiovascular Research Centre; University of Glasgow; 126 University Place Glasgow G12 8TA UK

name: Preventative Health; Baker IDI Heart and Diabetes Institute; Melbourne Australia

name: Department of Internal Medicine, Faculty of Medicine; Universitätsklinikum des Saarlandes; Homburg/Saar Germany

name: Sahlgrenska University Hospital/Östra, Institute of Medicine, Department of Emergency and Cardiovascular medicine, Sahlgrenska Academy; Gothenburg University; Gothenburg Sweden

name: Department of Cardiology; University Medical Center; Groningen The Netherlands

name: Department of Cardiology, Thoraxcenter; University Medical Center; Groningen The Netherlands

name: Wallenberg Laboratory for Cardiovascular Research; Sahlgrenska Academy, Gothenburg University; Gothenburg Sweden

name: Department of Cardiology, Rikshospitalet University Hospital; University of Oslo; Norway

name: Nordic School of Public Health; Göteborg Sweden

ReferenceCitation: McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009 Dec 1;120(22):2188-96. doi: 10.1161/CIRCULATIONAHA.109.849117. Epub 2009 Nov 16. Erratum in: Circulation. 2010 Jun 29;121(25):e461.

name: From the BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK (J.J.V.M.); Department of Cardiology, Rikshospitalet University Hospital, Oslo, Norway (J. Kjekshus, L.G.); Amphia Hospital, Breda, the Netherlands (P.D.); Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden (A.H., F.W., J.W.); Nordic School of Public Health, Gothenburg, Sweden (H.W.); AstraZeneca, Mölndal, Sweden (M.L.); The Heart Center, Rigshospitalet, Copenhagen University, Copenhagen, Denmark (P...

title: Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

ReferenceCitation: Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007 Nov 29;357(22):2248-61. Epub 2007 Nov 5.

location_country:
Finland
Romania
Belgium
Russian Federation
Denmark
Czech Republic
France
Poland
Slovakia
Norway
South Africa
Sweden
Switzerland
Netherlands
Bulgaria
Hungary
Ireland
Portugal
Germany
United Kingdom
Spain


title: A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis

summary: This study will provide a direct comparison of 'continuous therapy' and 'intermittent therapy' with withdrawal and retreatment upon return of psoriasis.

primary_purpose: Treatment

ReferenceCitation: Griffiths CE, Christophers E, Szumski A, Jones H, Mallbris L. Impact of early vs. late disease onset on treatment response to etanercept in patients with psoriasis. Br J Dermatol. 2015 Nov;173(5):1271-3. doi: 10.1111/bjd.13865. Epub 2015 Aug 17.

name: Dermatology Centre; Manchester Academic Health Science Centre; Salford Royal Hospital; University of Manchester; M6 8HD Manchester U.K

family: Griffiths

full_name: C.E.M. Griffiths

family: Christophers

full_name: E. Christophers

given: E.

name: Specialty Care; Pfizer Inc; Collegeville PA U.S.A

family: Szumski

full_name: A. Szumski

given: A.

family: Jones

full_name: H. Jones

given: H.

family: Mallbris

full_name: L. Mallbris

given: L.

journal_name: British Journal of Dermatology

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

ReferenceCitation: Griffiths CE, Luger TA, Brault Y, Germain JM, Mallbris L. Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):468-73. doi: 10.1111/jdv.12585. Epub 2014 Aug 4.

name: Dermatology Centre; Salford Royal Hospital; University of Manchester; Manchester Academic Health Science Centre; Manchester UK

name: Department of Dermatology; University of Muenster; Muenster Germany

family: Luger

full_name: T.A. Luger

family: Brault

full_name: Y. Brault

given: Y.

name: Pfizer; Pfizer International Operations; Paris France

family: Germain

full_name: J.M. Germain

name: Global Medical Affairs; Global Innovative Pharma; Pfizer Inc; Collegeville PA USA

journal_name: Journal of the European Academy of Dermatology and Venereology

lead_sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

location_country:
Italy
Austria
Sweden
Switzerland
Netherlands
Spain
United Kingdom
Finland
France
Poland
Greece
Norway
Hungary
Belgium
Portugal
Turkey
Denmark
Germany
Czech Republic


type: EudraCT Number

title: An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

summary: This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) in combination with ribavirin (RBV) with or without pegylated interferon (Peg-IFN) in adults with chronic hepatitis C virus (HCV) infection who participated in a prior Gilead HCV study and have not achieved sustained virologic response (SVR).

design_allocation: Non-Randomized

lead_sponsor: Gilead Sciences

location_country:
Italy
Austria
United States
Sweden
United Kingdom
Netherlands
Germany
France
Poland
Australia
Puerto Rico
New Zealand
Spain
Estonia
Canada
Czech Republic

location_facility: Bon Secours Saint Mary's Hospital of Richmond

location_facility: University of Miami Center for Liver Diseases

location_facility: Pointe West Infectious Diseases d/b/a Bach and Godofsky Infectious Diseases

location_facility: Fondazione PTV - Policlinico Tor Vergata

location_facility: Azienda Ospedaliero Universitaria di Parma

location_facility: Chelsea and Westminster Hospital NHS Foundation Trust

location_facility: Fondazione IRCCS CA Granada - Ospedale Maggiore Policlinico

location_facility: Remedis s.r.o., Nestátní zdravotnické zarízení

location_facility: Ente Ospedaliero Ospedali Galliera di Genova

location_facility: Hospital of the University of Pennsylvania

location_facility: The Gastroenterology Group of South Jersey

location_facility: Royal Free Hospital and University College London Hospital

location_facility: Kansas City Gastroenterology and Hepatology

location_facility: Centre Hospitalier Universitaire de Clermont-Ferrand

location_facility: Infectious Disease and The Research Institute

location_facility: Azienda Ospedaliero Universitaria S. Giovanni Battista di Torino

location_facility: Southern California Transplantation Institute, Research Foundation Liver Center

location_facility: PraxisZentrum für Gastroenterologie und Endokrinologie

location_facility: Radboud University Nijmegen Medical Centre (UMC St Radboud)

location_facility: University of California Davis Medical Center

location_facility: Hospital General Universitario de Valencia

location_facility: Hospital Clinico Universitario Virgen de la Victoria

location_facility: Vancouver Infectious Disease Research and Care Centre

location_facility: Medizinische Universitätsklinik IV (Krehl Klinik) Abt. Gastroenterologie und Infektionskrankheiten

location_facility: Atlanta Gastroenterology Associates, LLC

location_facility: Gordon & Leslie Diamond Health Care Centre

location_facility: Indianapolis Gastroenterology Research Foundation

location_facility: Hôpital Claude Huriez- Service d'Hépato-Gastroentérologie

location_facility: Centre Hospitalier Universitare de Rennes, Hôpital Pontchaillou

location_facility: Gastointestinal Specialists of Georgia, PC

location_facility: Azienda Ospedaliera Ospedale Niguarda Ca' Granda

location_facility: South Florida Center of Gastroenterology, PA.

location_facility: Centre Hospitalier Universitaire de Strasbourg

location_facility: Royal Prince Alfred Hospital, Camperdown

location_facility: Toronto Digestive Diseases Associates, Inc

location_facility: Klinikum und Fachbereich Medizin Johann Wolfgang Goethe-Universität Frankfurt am Main

location_facility: Binghamton Gastroenterology Associates, PC

location_facility: Gastrointestinal Research Institute (GIRI)

location_facility: Hospital Universitario Nuestra Señora de Valme

location_facility: Academic Hospital Rotterdam Erasmus Medical Center

location_facility: Annette C. and Harold C. Simmons Transplant Center

location_facility: Lightsource Medical/Peter J. Ruane MD, Inc.


title: A Prospective Registry of European Hemophilia B Patients Receiving BeneFIX®(Nonacog Alfa, Recombinant Human Factor IX) for Usual Use

summary: This is an open-label multi-center Registry in patients with hemophilia B receiving BeneFIX. All patients who begin treatment with BeneFIX in European Union countries, will be eligible for participation. Patient demographics will be collected at baseline for all patients. A baseline FIX activity and Bethesda assay for inhibitor based on historical data should be recorded if available. Adverse events as defined in the protocol will also be reported on the appropriate forms. Data will be collected from patients on an ongoing basis to ensure that information is being captured for each patient being treated with BeneFIX.

ReferenceCitation: Rendo P, Smith L, Lee HY, Shafer F. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis. 2015 Dec;26(8):912-8. doi: 10.1097/MBC.0000000000000359.

family: Rendo

full_name: Pablo Rendo

given: Pablo

family: Smith

full_name: Lynne Smith

given: Lynne

family: Lee

full_name: Hsiao-Yu Lee

given: Hsiao-Yu

family: Shafer

full_name: Frank Shafer

given: Frank

journal_name: Blood Coagulation & Fibrinolysis

title: Nonacog alfa

location_country:
Italy
Austria
Sweden
Netherlands
Spain
France
Belgium
Portugal
Germany
United Kingdom


title: A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE

summary:
Objectives of the study:

Primary: Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered once daily (QD) for 24 months in slowing disease progression as assessed radiographically in subjects with osteoarthritis (OA) of the hipSecondary:Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered QD for 24 months in treating disease signs and symptoms in subjects with OA of the hip.Evaluate the ability of a continuous 24-month intake of celecoxib 200 mg QD versus placebo to reduce number of subjects eligible for hip replacement according to the investigator.Evaluate the tolerability and safety of a continuous 24-month intake of celecoxib 200 mg QD versus placebo in subjects with OA of the hip.

status: Terminated

lead_sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

location_country: Canada France

status_simplified: Unknown


title: A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis

acronym: CAP

summary: The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.

ReferenceCitation: Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

family: Bonnet

full_name: Jacques Bonnet

given: Jacques

family: McPherson

full_name: R. McPherson

given: R.

family: Tedgui

full_name: A. Tedgui

family: Simoneau

full_name: D. Simoneau

given: D.

family: Nozza

full_name: A. Nozza

family: Martineau

full_name: P. Martineau

given: P.

family: Davignon

full_name: Jean Davignon

given: Jean

journal_name: Clinical Therapeutics

title: Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study

location_country:
France
Czechia
Poland
Slovakia
Romania
Russian Federation
Canada

intervention_type: Procedure


title: Carotid Atorvastatin Study In Hyperlipidemic Post-Menopausal Women: A Randomized Evaluation of Atorvastatin, Versus Placebo (CASHMERE)

summary: To evaluate the effect of atorvastatin 80 mg, versus placebo, given for 12 months on carotid intima-media thickness in postmenopausal women with moderate hypercholesterolemia.

ReferenceCitation: Gompel A, Boutouyrie P, Joannides R, Christin-Maitre S, Kearny-Schwartz A, Kunz K, Laurent S, Boivin JM, Pannier B, Pornel B, Struijker-Boudier HA, Thuillez C, Van Bortel L, Zannad F, Pithois-Merli I, Jaillon P, Simon T. Association of menopause and hormone replacement therapy with large artery remodeling. Fertil Steril. 2011 Dec;96(6):1445-50. doi: 10.1016/j.fertnstert.2011.09.010. Epub 2011 Oct 6.

family: Gompel

full_name: Anne Gompel

given: Anne

family: Boutouyrie

full_name: Pierre Boutouyrie

given: Pierre

family: Joannides

full_name: Robinson Joannides

given: Robinson

family: Christin-Maitre

full_name: Sophie Christin-Maitre

given: Sophie

family: Kearny-Schwartz

full_name: Anna Kearny-Schwartz

given: Anna

family: Kunz

full_name: Kristian Kunz

given: Kristian

family: Laurent

full_name: Stéphane Laurent

given: Stéphane

family: Boivin

full_name: Jean-Marc Boivin

given: Jean-Marc

family: Pannier

full_name: Bruno Pannier

given: Bruno

family: Pornel

full_name: Bernard Pornel

given: Bernard

family: Struijker-Boudier

full_name: Harry A.J. Struijker-Boudier

given: Harry A.J.

family: Thuillez

full_name: Christian Thuillez

given: Christian

family: Van Bortel

full_name: Luc Van Bortel

given: Luc

family: Zannad

full_name: Faied Zannad

given: Faied

family: Pithois-Merli

full_name: Isabelle Pithois-Merli

given: Isabelle

family: Jaillon

full_name: Patrice Jaillon

given: Patrice

family: Simon

full_name: Tabassome Simon

given: Tabassome

journal_name: Fertility and Sterility

location_country: Belgium France Netherlands